Working Note: Great Eastern Life

Knowledge Snapshot

Last updated: 2026-06-12

Issuer Overview

• The Great Eastern Life Assurance Company Limited (GEL) is the core Singapore life insurance subsidiary of Great Eastern Holdings Limited (GEH).
• GEH is the insurance arm of the OCBC group. OCBC described its GEH economic interest as about 93.72% after the 2025 Class C non-voting share structure changes. This is group-support context, not an explicit legal guarantee for GEL securities.
• Public detailed financial information used in the current reports is mainly GEH consolidated data. GEL standalone audited financial statements were not retrieved from ACRA for the initial coverage work.

Core Credit Context

• GEL should be analyzed as a life insurer with long-duration insurance contract liabilities and a large investment portfolio, not as a bank, general corporate, or OCBC bank debt.
• The main credit drivers are insurance contract liabilities, investment assets, interest-rate and market valuation movements, medical claims, CSM, asset-liability management, regulatory capital, and the OCBC/GEH relationship.
• GEH consolidated FY2025 and 1Q2026 disclosures showed strong insurance earnings and new business value, while 1Q2026 also showed that shareholders' fund profit and OCI remain sensitive to bond and equity market valuation.

Business and Group Structure

• Great Eastern is an insurance group founded in 1908, with core markets in Singapore and Malaysia and operations also in Indonesia and Brunei.
• At end-2025, GEH reported more than 16 million customers, including 11.7 million government-scheme customers.
• Distribution includes agency, bancassurance, financial advisers, direct digital channels, digital partnerships, and relationships with OCBC and Bank of Singapore.
• FY2025 materials described a shift away from short-term single-premium products toward a more diversified and longer-term product mix. TWNS declined in FY2025 while NBEV increased; 1Q2026 TWNS and NBEV both increased year on year.

Financial and Balance Sheet Context

• GEH consolidated FY2025 reported total assets of S$122.6bn, total investments of S$109.0bn, gross insurance contract liabilities of S$107.1bn, net insurance contract liabilities of S$105.8bn, profit attributable to shareholders of S$1.207bn, TWNS of S$1.535bn, and NBEV of S$739.7mn.
• GEH consolidated 1Q2026 reported TWNS of S$401.9mn, NBEV of S$195.4mn, profit from insurance business of S$329.0mn, group profit attributable to shareholders of S$346.3mn, and negative OCI of S$2.6mn.
• Detailed figures, balance-sheet items, ratings, and capital-security facts are stored in data/great_eastern_life_key_metrics_20260514.json.

Capital Structure and Instruments

• GEL issued S$500mn of 3.928% subordinated notes due 2039, first callable in 2034, under the GEH/GEL EMTN programme.
• GEL issued US$500mn of 5.398% fixed-rate perpetual capital securities, first callable in 2032, in January 2025. The pricing announcement described these as direct, unsecured and subordinated obligations expected to qualify as Additional Tier 1 capital of GEL, with non-cumulative discretionary distributions.
• The initial coverage did not retrieve the final Offering Circulars or trust deeds for the capital securities, so precise loss-absorption, distribution, call, regulatory-event, tax-event, default, and ranking provisions are not confirmed in the memory files.

Ratings

• The official Great Eastern rating page accessed on 2026-05-14 showed GEL insurer financial strength ratings of S&P AA- / Stable and Fitch AA / Stable.
• Fitch's 2025 first-time rating release described GEL with IFS AA / Stable and long-term IDR AA- / Stable, and treated the major GEH insurance subsidiaries as core to the broader group support framework.

Credit Strengths

• Long operating history, strong Singapore and Malaysia franchise, broad distribution, and a large policyholder base support business stability.
• GEH consolidated scale, investment assets, earnings capacity, embedded value, and comprehensive equity provide a strong group-level base for assessing GEL.
• AA-range insurer financial strength ratings and the strategic relationship with OCBC support funding access and normal-period support expectations.

Credit Weaknesses and Structural Constraints

• GEL standalone audited financials and precise standalone regulatory capital ratios were not obtained in the initial coverage.
• Large investment assets and insurance liabilities make earnings, OCI, comprehensive equity, and capital sensitive to interest rates, credit spreads, equities, medical claims, policyholder behavior, and actuarial assumptions.
• AT1 and Tier 2 securities carry security-specific risks that differ from senior issuer credit and insurer financial strength.

Reliable Core Sources

• GEH Annual Report 2025; GEH FY2025 media release and financial summary; GEH 1Q2026 media release and financial summary.
• Great Eastern official stock information and credit ratings page.
• Fitch 2025 first-time rating release; GEL AT1 and Tier 2 issue announcements; OCBC 2025 GEH ownership and delisting/free-float releases.
• data/great_eastern_life_key_metrics_20260514.json for structured extracted figures and source metadata.

Issuer Notes

Last updated: 2026-06-12

Ongoing Follow-Up Items

• Track GEH FY2026 interim and full-year disclosures, especially TWNS, NBEV, insurance business profit, shareholders' fund profit, OCI, TCI, EV, CE, and commentary on Singapore and Malaysia channels.
• Monitor medical claims, repricing, loss components, product redesign, reinsurance, and customer/regulatory response in Singapore and Malaysia.
• Monitor investment-market sensitivity through bond valuation, equity valuation, credit spreads, OCI, comprehensive equity, and any capital-ratio commentary.
• Track OCBC's GEH ownership structure, free-float solution, strategic wording for GEH, and any renewed delisting or group restructuring proposal.
• Monitor any additional GEL or GEH capital-securities issuance and market treatment of existing AT1/Tier 2 securities.

Unresolved Issues and Items to Check Next Time

• Obtain GEL standalone audited financial statements through ACRA or another official channel if issuer-level precision is required.
• Confirm GEL standalone MAS capital adequacy ratio, available capital, required capital, capital buffer, and stress sensitivity.
• Obtain final Offering Circulars and trust deeds for the US$500mn 5.398% AT1 and S$500mn 3.928% Tier 2 instruments.
• Confirm current instrument-level ratings, call assumptions, market prices, yields, spreads, liquidity, and peer insurer capital-security comparisons.
• Confirm medical insurance claims ratios, loss-component detail, CSM movement by product, surrender behavior, reinsurance terms, investment portfolio duration, currency, rating mix, and hedge profile.

Analytical Cautions

• Do not treat GEH consolidated figures as GEL standalone figures. Use GEH data as group context unless a GEL-specific source has been confirmed.
• Distinguish OCBC/GEH strategic support expectations from an explicit legal guarantee. GEL securities should not be described as OCBC bank debt.
• Do not equate insurer financial strength ratings with AT1 or Tier 2 security risk. Capital securities require separate treatment for coupon cancellation, subordination, redemption approval, and loss absorption.
• Do not read lower TWNS alone as franchise deterioration when company materials attribute part of the change to product-mix shift; also do not treat NBEV as immediately available cash or regulatory capital.
• Do not conclude that 1Q2026 reserve releases or insurance profit growth resolved medical-claims risk; the disclosure did not provide enough detail.

Report Wording Cautions

• State clearly when figures are GEH consolidated rather than GEL standalone.
• When discussing OCBC, use support-context language rather than guarantee language.
• For AT1 and Tier 2, use "not confirmed" wording for write-down, conversion, distribution stopper, non-viability, regulatory call, tax call, event of default, cross-default, and liquidation-ranking details until the transaction documents are reviewed.
• Avoid buy/hold/sell language unless live market levels, security terms, and peer spreads have been reviewed.

Follow-Up on Management Strategy, Investment Plans, and Financial Policy

• Watch whether product-mix changes continue to favor longer-duration and higher-value products without increasing guarantee, lapse, medical-claims, or capital-consumption risk.
• Track OCBC/GEH capital management, free-float actions, dividend behavior, and capital-security use.
• Monitor whether management discloses more granular regulatory capital, investment, medical-claims, and product profitability data.

Items to Check for Ratings and Bond Investors

• Fitch and S&P rating actions, outlooks, and support assessment, including any change in OCBC rating, GEH core status, Prism score, financial leverage, NBV, ROE, or medical-claims assumptions.
• Current AT1 and Tier 2 pricing, first-call expectations, rating notching, and comparable Asian insurer capital-security spreads.
• Any MAS or accounting developments that affect insurance capital recognition, capital-security redemption, CSM, or insurer OCI.